Shionogi takes further action as US challenges drag down 1Q
This article was originally published in Scrip
Executive Summary
Shionogi is continuing to grapple with challenges at its US operations following the 2008 acquisition of Sciele Pharma, and has cut its sales forecast for this market in the wake of returns of expired products.